Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > Sernova can easily afford to drive business growth.
View:
Post by rixpix on Aug 16, 2021 1:24pm

Sernova can easily afford to drive business growth.

Don't know of anyone's seen this. It's a few days old. Worth the read.... https://simplywall.st/stocks/ca/pharmaceuticals-biotech/tsxv-sva/sernova-shares/news/we-think-sernova-cvesva-can-easily-afford-to-drive-business
Comment by MustangSalley on Aug 16, 2021 1:33pm
  Rip, Thanks for posting that . It is a purely amateur assessment of Sva . Firstly , Thayer Sva listed on Cse not Tsx Venture exchange. Their assessment that annual 6.1 million burn rate will last 5 years before they will have to raise money is unrealistic . Toleisikiscis doubling the staff and any clinica  studies for Thyorid or even an expansion of the current Fda trial will eat ...more  
Comment by Metalsguy1 on Aug 16, 2021 2:00pm
SVA has failed at every approach. This would be no different.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities